{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:33:23Z","timestamp":1792611203354,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier","isbn-type":[{"value":"9780128177389","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672585"],"award-info":[{"award-number":["81672585"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2018.12.013","type":"book-chapter","created":{"date-parts":[[2019,2,23]],"date-time":"2019-02-23T12:23:56Z","timestamp":1550924636000},"page":"377-390","source":"Crossref","is-referenced-by-count":15,"title":["Serum PSA levels in patients with prostate cancer and other 33 different types of diseases"],"prefix":"10.1016","member":"78","reference":[{"issue":"13","key":"10.1016\/bs.pmbts.2018.12.013_bb0010","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.ejca.2007.06.006","article-title":"PSA and other tissue kallikreins for prostate cancer detection","volume":"43","author":"Stephan","year":"2007","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.013_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0090-4295(03)00775-1","article-title":"Biology of prostate-specific antigen","volume":"62","author":"Lilja","year":"2003","journal-title":"Urology"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0020","first-page":"1226","article-title":"Purification of a human prostate specific antigen 1","volume":"167","author":"Wang","year":"1979","journal-title":"Invest Urol"},{"issue":"12","key":"10.1016\/bs.pmbts.2018.12.013_bb0025","first-page":"4658","article-title":"Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay","volume":"40","author":"Kuriyama","year":"1980","journal-title":"Cancer Res"},{"issue":"15","key":"10.1016\/bs.pmbts.2018.12.013_bb0030","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM198710083171501","article-title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","volume":"317","author":"Stamey","year":"1987","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/bs.pmbts.2018.12.013_bb0035","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/clinchem\/37.9.1618","article-title":"Prostate specific antigen in serum occurs predominantly in complex with an alpha 1 chymotrypsin","volume":"37","author":"Lilja","year":"1991","journal-title":"Clin Chem"},{"key":"10.1016\/bs.pmbts.2018.12.013_bb0040","first-page":"222","article-title":"A complex between prostate-specific antigen and \u03b11-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer","volume":"51","author":"Stenman","year":"1991","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0045","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0009-9120(95)91342-Z","article-title":"A guide to the interpretation of serum prostate specific antigen levels","volume":"28","author":"Bunting","year":"1995","journal-title":"Clin Biochem"},{"issue":"22","key":"10.1016\/bs.pmbts.2018.12.013_bb0050","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0055","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2007.10.047","article-title":"Early detection of prostate cancer in 2007","volume":"53","author":"Schr\u00f6der","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0022-5347(01)67064-2","article-title":"Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels","volume":"154","author":"Nadler","year":"1995","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.013_bb0065","first-page":"387","article-title":"Effect of ejaculation on serum prostate specific antigen level in screening and non-screening population","volume":"18","author":"Mohammad","year":"2013","journal-title":"J Res Med Sci"},{"issue":"16","key":"10.1016\/bs.pmbts.2018.12.013_bb0070","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.1992.03480160085039","article-title":"The effect of digital rectal examination on prostate-specific antigen levels","volume":"267","author":"Crawford","year":"1992","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0075","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0094-0143(05)70374-8","article-title":"The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration","volume":"24","author":"Tchetgen","year":"1997","journal-title":"Urol Clin North Am"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.013_bb0080","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.urology.2005.06.077","article-title":"Effect of prostatic massage on serum complexed prostate-specific antigen levels","volume":"66","author":"Fatih","year":"2005","journal-title":"Urology"},{"issue":"7","key":"10.1016\/bs.pmbts.2018.12.013_bb0085","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jama.1993.03510070082041","article-title":"Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges","volume":"270","author":"Oesterling","year":"1993","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0090","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2013.08.060","article-title":"Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies","volume":"66","author":"Cary","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-5347(17)37393-7","article-title":"Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer","volume":"147","author":"Benson","year":"1992","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.013_bb0100","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.juro.2010.01.001","article-title":"Risk stratification of men choosing surveillance for low risk prostate cancer","volume":"183","author":"Tseng","year":"2010","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0105","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.eururo.2008.06.040","article-title":"Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer\u2014a review","volume":"54","author":"van den Bergh","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.013_bb0110","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/ijc.22161","article-title":"PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section","volume":"120","author":"Ali","year":"2010","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0115","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1464-410X.2007.07190.x","article-title":"Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience","volume":"101","author":"Soloway","year":"2010","journal-title":"BJU Int"},{"issue":"15","key":"10.1016\/bs.pmbts.2018.12.013_bb0120","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jama.1995.03530150038031","article-title":"Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening","volume":"274","author":"Catalona","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0302-2838(02)00256-7","article-title":"Repeat prostate biopsy: who, how and when? A review","volume":"42","author":"Bob","year":"2002","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.013_bb0130","first-page":"475","article-title":"Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 3\u201310ng\/mL: a Zimbabwean perspective","volume":"3","author":"Marima-Matarira","year":"2014","journal-title":"Int J Sci Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0135","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.juro.2011.10.133","article-title":"Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion","volume":"187","author":"Maciej","year":"2012","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0140","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.urology.2013.12.005","article-title":"Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores \u2265100","volume":"83","author":"SchrDer","year":"2014","journal-title":"Urology"},{"issue":"5","key":"10.1016\/bs.pmbts.2018.12.013_bb0145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haesea","year":"2008","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.013_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0090-4295(99)00372-6","article-title":"\u201cB-PSA,\u201d a specific molecular form of free prostate specific antigen, is found predominantly in the transition zone of patients with nodular BPH","volume":"55","author":"Mikolajczyk","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0155","first-page":"756","article-title":"A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue","volume":"60","author":"Mikolajczyk","year":"2000","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0160","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2302\/kjm.52.86","article-title":"Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer","volume":"52","author":"Mikolajczyk","year":"2003","journal-title":"Keio J Med"},{"issue":"sup221","key":"10.1016\/bs.pmbts.2018.12.013_bb0165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3109\/00365519509090561","article-title":"Clinical usefulness of free and complexed PSA","volume":"55","author":"Prestigiacomo","year":"1995","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"10.1016\/bs.pmbts.2018.12.013_bb0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.juro.2006.09.039","article-title":"Prostate specific antigen density correlates with features of prostate cancer aggressiveness","volume":"177","author":"Kundu","year":"2007","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/bs.pmbts.2018.12.013_bb0175","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.urology.2007.01.087","article-title":"Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure","volume":"69","author":"Radwan","year":"2007","journal-title":"Urology"},{"issue":"19","key":"10.1016\/bs.pmbts.2018.12.013_bb0180","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jama.279.19.1542","article-title":"Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial","volume":"279","author":"Catalona","year":"1998","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/bs.pmbts.2018.12.013_bb0185","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1442-2042.2004.00843.x","article-title":"Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy","volume":"11","author":"Uemura","year":"2004","journal-title":"Int J Urol"},{"issue":"18","key":"10.1016\/bs.pmbts.2018.12.013_bb0190","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.1997.03540420048028","article-title":"Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0ng\/mL and benign prostate examination. Enhancement of specificity with free PSA measurements","volume":"277","author":"Catalona","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/bs.pmbts.2018.12.013_bb0195","unstructured":"Brosman S.A, n.d. eMedicine: Prostate-Specific Antigen. WebMD. Retrieved 2008-05-11."},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.013_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0009-8981(01)00749-5","article-title":"Development and validation of a quantitative ELISA for the measurement of PSA concentration","volume":"317","author":"Acevedo","year":"2002","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.013_bb0205","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15321819.2017.1392320","article-title":"Extraction, purification of prostate-specific antigen (PSA), and establishment of radioimmunoassay system as a diagnostic tool for prostate disorders","volume":"39","author":"Abu-Bakr El-Bayoumy","year":"2018","journal-title":"J Immunoassay Immunochem"},{"issue":"3","key":"10.1016\/bs.pmbts.2018.12.013_bb0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bios.2014.06.015","article-title":"Rapid aptasensor capable of simply diagnosing prostate cancer","volume":"62","author":"Cha","year":"2014","journal-title":"Biosens Bioelectron"},{"issue":"13","key":"10.1016\/bs.pmbts.2018.12.013_bb0215","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/elan.200804194","article-title":"Electrochemical immunoassay for free prostate specific antigen (f-PSA) using magnetic beads","volume":"20","author":"Sarkar","year":"2010","journal-title":"Electroanalysis"},{"key":"10.1016\/bs.pmbts.2018.12.013_bb0220","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ab.2018.11.020","article-title":"A molecularly imprinted electrochemical nanobiosensor for prostate specific antigen determination","volume":"566","author":"Yazdani","year":"2018","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/bs.pmbts.2018.12.013_bb0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ab.2011.12.047","article-title":"Label-free electrochemical immunosensor based on graphene\/methylene blue nanocomposite","volume":"422","author":"Kexia","year":"2012","journal-title":"Anal Biochem"},{"issue":"4","key":"10.1016\/bs.pmbts.2018.12.013_bb0230","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic Analysis for the Global Burden of Disease Study","volume":"3","author":"Fitzmaurice","year":"2017","journal-title":"JAMA Oncol"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877117318301613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T03:59:32Z","timestamp":1761796772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877117318301613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177389"],"references-count":45,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2018.12.013","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}